Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ASND NASDAQ:AXSM NASDAQ:BBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.62+0.1%$21.70$19.69▼$28.35$3.70B0.831.64 million shs3.23 million shsASNDAscendis Pharma A/S$230.83-0.1%$232.16$160.86▼$250.74$14.40B0.39681,869 shs891,707 shsAXSMAxsome Therapeutics$250.50-0.7%$215.95$96.09▼$260.19$12.89B0.61695,788 shs770,653 shsBBIOBridgeBio Pharma$66.27-1.7%$69.89$40.19▼$84.94$12.98B0.972.78 million shs3.82 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+3.15%+1.65%+4.40%+4.25%-5.26%ASNDAscendis Pharma A/S-0.02%+10.18%-2.73%+3.48%+33.69%AXSMAxsome Therapeutics+0.10%+2.36%+10.89%+58.71%+148.19%BBIOBridgeBio Pharma+1.13%-0.01%+3.17%-3.96%+68.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.62+0.1%$21.70$19.69▼$28.35$3.70B0.831.64 million shs3.23 million shsASNDAscendis Pharma A/S$230.83-0.1%$232.16$160.86▼$250.74$14.40B0.39681,869 shs891,707 shsAXSMAxsome Therapeutics$250.50-0.7%$215.95$96.09▼$260.19$12.89B0.61695,788 shs770,653 shsBBIOBridgeBio Pharma$66.27-1.7%$69.89$40.19▼$84.94$12.98B0.972.78 million shs3.82 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+3.15%+1.65%+4.40%+4.25%-5.26%ASNDAscendis Pharma A/S-0.02%+10.18%-2.73%+3.48%+33.69%AXSMAxsome Therapeutics+0.10%+2.36%+10.89%+58.71%+148.19%BBIOBridgeBio Pharma+1.13%-0.01%+3.17%-3.96%+68.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.67Moderate Buy$31.6346.28% UpsideASNDAscendis Pharma A/S 3.00Buy$295.3927.97% UpsideAXSMAxsome Therapeutics 2.95Moderate Buy$258.953.37% UpsideBBIOBridgeBio Pharma 2.84Moderate Buy$91.0537.39% UpsideCurrent Analyst Ratings BreakdownLatest ACAD, ASND, AXSM, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026AXSMAxsome Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$275.00 ➝ $300.006/16/2026BBIOBridgeBio Pharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$106.00 ➝ $96.006/15/2026AXSMAxsome Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/11/2026AXSMAxsome Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$380.006/11/2026AXSMAxsome Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeReduce ➝ Overweight6/9/2026ASNDAscendis Pharma A/S OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/4/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026BBIOBridgeBio Pharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$104.005/28/2026BBIOBridgeBio Pharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$94.00 ➝ $98.005/28/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$110.005/26/2026BBIOBridgeBio Pharma Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B3.46$0.92 per share23.60$7.25 per share2.98ASNDAscendis Pharma A/S$814.57M17.68N/AN/A($2.97) per share-77.72AXSMAxsome Therapeutics$638.50M20.19N/AN/A$1.75 per share143.14BBIOBridgeBio Pharma$502.08M25.85N/AN/A($10.77) per share-6.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.209.8327.3726.2934.30%9.61%7.07%8/5/2026 (Estimated)ASNDAscendis Pharma A/S-$258M$8.6726.6221.49N/A57.87%N/A-8.37%8/6/2026 (Estimated)AXSMAxsome Therapeutics-$183.17M-$3.73N/A51.65N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)BBIOBridgeBio Pharma-$724.93M-$3.74N/A288.13N/A-124.42%N/A-65.81%8/4/2026 (Estimated)Latest ACAD, ASND, AXSM, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48ASNDAscendis Pharma A/S0.791.000.72AXSMAxsome Therapeutics2.271.391.32BBIOBridgeBio PharmaN/A1.521.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ASNDAscendis Pharma A/SN/AAXSMAxsome Therapeutics81.49%BBIOBridgeBio Pharma99.85%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%ASNDAscendis Pharma A/S40.00%AXSMAxsome Therapeutics20.60%BBIOBridgeBio Pharma14.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableAXSMAxsome Therapeutics38051.46 million40.86 millionOptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableACAD, ASND, AXSM, and BBIO HeadlinesRecent News About These CompaniesBridgeBio Pharma (NASDAQ:BBIO) Director Jennifer Cook Sells 90,240 SharesJune 18 at 7:17 AM | insidertrades.comIshara Investments LP Makes New $2.75 Million Investment in BridgeBio Pharma, Inc. $BBIOJune 18 at 6:12 AM | marketbeat.comJanus Henderson Group PLC Acquires 2,259,378 Shares of BridgeBio Pharma, Inc. $BBIOJune 18 at 6:12 AM | marketbeat.comBridgeBio Pharma, Inc. $BBIO Shares Sold by Cinctive Capital Management LPJune 18 at 5:18 AM | marketbeat.comBridgeBio Pharma, Inc. $BBIO Position Lessened by Cormorant Asset Management LPJune 18 at 4:59 AM | marketbeat.comBridgeBio Pharma, Inc. $BBIO Shares Sold by Boone Capital Management LLCJune 18 at 4:13 AM | marketbeat.comBridgeBio Pharma, Inc. $BBIO Shares Sold by Granahan Investment Management LLCJune 17 at 6:33 AM | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Given New $96.00 Price Target at MizuhoJune 16 at 8:37 AM | marketbeat.comSofinnova Investments Inc. Sells 111,399 Shares of BridgeBio Pharma, Inc. $BBIOJune 16 at 6:46 AM | marketbeat.com2,750,000 Shares in BridgeBio Pharma, Inc. $BBIO Purchased by Brooklands Fund Management LtdJune 16 at 3:22 AM | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Average Rating of "Moderate Buy" from BrokeragesJune 15 at 2:32 AM | americanbankingnews.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by AnalystsJune 15 at 2:31 AM | marketbeat.comBridgeBio Pharma, Inc. $BBIO is Frazier Life Sciences Management L.P.'s 4th Largest PositionJune 14, 2026 | marketbeat.comEventide Asset Management LLC Reduces Holdings in BridgeBio Pharma, Inc. $BBIOJune 14, 2026 | marketbeat.comMonashee Investment Management LLC Sells 100,000 Shares of BridgeBio Pharma, Inc. $BBIOJune 12, 2026 | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)June 10, 2026 | marketbeat.comBridgeBio Pharma, Inc. $BBIO Shares Acquired by GW&K Investment Management LLCJune 10, 2026 | marketbeat.comBridgeBio Pharma, Inc. $BBIO Position Lifted by Franklin Resources Inc.June 10, 2026 | marketbeat.comAxiom Investors LLC DE Has $15.87 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIOJune 10, 2026 | marketbeat.comBridgeBio Pharma Inc.June 9, 2026 | barrons.comTD Asset Management Inc Boosts Stake in BridgeBio Pharma, Inc. $BBIOJune 9, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACAD, ASND, AXSM, and BBIO Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$21.62 +0.02 (+0.09%) Closing price 04:00 PM EasternExtended Trading$21.56 -0.06 (-0.28%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Ascendis Pharma A/S NASDAQ:ASND$230.83 -0.32 (-0.14%) Closing price 04:00 PM EasternExtended Trading$230.22 -0.61 (-0.26%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Axsome Therapeutics NASDAQ:AXSM$250.50 -1.66 (-0.66%) Closing price 04:00 PM EasternExtended Trading$250.69 +0.19 (+0.08%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.BridgeBio Pharma NASDAQ:BBIO$66.27 -1.12 (-1.66%) Closing price 04:00 PM EasternExtended Trading$66.31 +0.04 (+0.06%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
